Literature DB >> 31453828

Understanding patient motivations for HIV pre-exposure prophylaxis initiation and adherence.

Minseung Chu1, Karen Cotler, Charles Yingling.   

Abstract

Consistent dosing of tenofovir/emtricitabine-based HIV pre-exposure prophylaxis (PrEP) can reduce HIV infection risk by up to 92%. However, clinical trials have shown low PrEP adherence (34-71%), resulting in reduced effectiveness. To improve PrEP's effectiveness, adherence to a daily PrEP regimen is essential. This report explores patients' patterns of PrEP initiation and use and their PrEP-related perceptions to provide greater understanding of patient motivations for beginning and adhering to PrEP. At two urban primary care clinics, individual coaching sessions that included semistructured interviews were offered to 10 PrEP patients. Regarding PrEP initiation, 30% of patients were advised to use PrEP by their nurse practitioners (NPs), while the remaining patients requested PrEP themselves. Before they initiated PrEP, all patients were familiar with it through social contacts or internet-based research. Patients' PrEP-related perceptions were identified, including perceived pros and cons of PrEP use, and degrees of PrEP knowledge, uncertainty, and fear. Primary care NPs should take detailed sexual histories to avoid overlooking PrEP candidates. In addition, primary care NPs should introduce easy-to-access, Internet-based resources to reinforce patient education. Last, PrEP promotional campaigns should be focused at the community level in gay, bisexual, transgender and queer populations.

Entities:  

Mesh:

Year:  2020        PMID: 31453828     DOI: 10.1097/JXX.0000000000000282

Source DB:  PubMed          Journal:  J Am Assoc Nurse Pract        ISSN: 2327-6886            Impact factor:   1.165


  1 in total

1.  Factors motivating female sex workers to initiate pre- exposure prophylaxis for HIV prevention in Zimbabwe.

Authors:  Definate Nhamo; Sinegugu E Duma; Elizabeth B Ojewole; Dixon Chibanda; Frances M Cowan
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.